Please assess the completion status of the following clinical trial:

Trial Title: The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously received and tolerated ALN-TTR02 (patisiran) in Study ALN-TTR02-002.~* Adequate Karnofsky performance status, liver function, and renal function.~Exclusion Criteria:~* Pregnant or nursing.~* Has had a liver transplant.~* Has a New York Heart Association heart failure classification \>2.~* Has unstable angina.~* Has uncontrolled clinically significant cardiac arrhythmia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ALN-TTR02 (patisiran) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).